⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 9, 2026Neurology

Samelisant (SUVN-G3031) for the Treatment of Cataplexy in Patients With Narcolepsy Type-one: Rationale and Study Design of a Phase-two Study (P6-14.008)

Pradeep Jayarajan Vinod Kumar Goyal A.S. Shinde Satish Jetta Veera Raghava Chowdary Palacharla Vijay Benade Renny Abraham Santosh Kumar Pandey Ramkumar Subramanian Abdul Rasheed Mohammed Ramakrishna Nirogi

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to assess the efficacy of Samelisant in treating cataplexy for narcolepsy type-one patients.
Phase-two clinical trial design to evaluate treatment outcomes
Focus on patients diagnosed with narcolepsy type-one
Involves assessment of cataplexy symptoms management
Results will determine the effectiveness of Samelisant compared to the current treatment options
Expectations include improvement in cataplexy frequency and severity

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Phase-two trial evaluates Samelisant's effectiveness in managing cataplexy, suggesting a new treatment option.

Abstract

To evaluate the potential utility of Samelisant for the management of cataplexy

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jayarajan et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3b4faef96ed7f05619e https://doi.org/10.1212/wnl.0000000000213202

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Samelisant (SUVN-G3031) - Topline Results from the Phase-2 Proof-of-Concept Double-blind, Placebo-controlled Study in Patients with Narcolepsy (P10-9.002)2024 · 1 citations
21171 Study Design and Rationale for a Phase-2 Study of Samelisant (SUVN-G3031) for the Treatment of Cataplexy in Patients with Type 1 NarcolepsyHuman Clinical Trial · 2026
30649 Samelisant Improves the Symptoms of Excessive Daytime Sleepiness in Narcolepsy: Results from a Phase-2 Study2024
40730 Samelisant (SUVN-G3031) Demonstrates Significant Reduction in Excessive Daytime Sleepiness in Patients with Narcolepsy: Phase-2 ResultsOriginal Research · 2026
51021 Samelisant: Clinician and Patient Global Impression from a Double-Blind, Phase-2 Study in Patients with Narcolepsy2024

More related papers

0756 Phase-3 Clinical Development of Samelisant: Rationale and Study Design for Treating Excessive Daytime Sleepiness in Patients with Narcolepsy2026
0637 Composite Response with Once-Nightly Sodium Oxybate: Symptom Improvement in Participants with Narcolepsy Type 12024
Treatment paradigms for cataplexy in narcolepsy: past, present, and future2015

More from Neurology

Recanalization After Acute Cervical Artery DissectionTue,
Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSDTue,